TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00815893
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 1.0 mcg/kg infusion for 10minutes
Study: NCT00815893
Drug: propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion.
Study: NCT00003968
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02095704
Drug: paracetamol tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
Study: NCT04039217
Drug: Biktarvy
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
Study: NCT00106353
Drug: Torisel
Normalized name: Torisel
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
Study: NCT01059318
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
Study: NCT03397914
Drug: Colistimethate Sodium
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
Study: NCT01244828
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
Study: NCT03015740
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01278797
Drug: Telmisartan/Amlodipine Combination Tablet
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination Tablet
Study: NCT01278797
Drug: Amlodipine Monocomponent
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00681928
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As determined by the subject's physician
Study: NCT00681928
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As determined by the subject's physician
Study: NCT00588354
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 or 400 micrograms clonidine
Study: NCT00588354
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 or 80 milligrams triamcinolone
Study: NCT00588354
Drug: Lidocaine HCl
Normalized name: lidocaine HCl
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml 2% lidocaine (20 mg/mL)
Study: NCT04571489
Drug: Gimatecan
Normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
Study: NCT04571489
Drug: tegafur, gimeracil and oteracil potassium
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
Study: NCT04571489
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
Study: NCT00345306
Drug: Comparison between two different progesterone administration
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008697
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00895713
Drug: intramuscular hepatitis B virus immune globulin
Normalized name: Hepatitis B Immune Globulin
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
Study: NCT01966783
Drug: Budesonide 2 mg suppository
Normalized name: budesonide 0.2 MG
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: per day
Study: NCT01966783
Drug: Budesonide 4 mg suppository
Normalized name: budesonide 4 MG
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: per day
Study: NCT01966783
Drug: Mesalazine 1 g suppository
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per day
Study: NCT01966783
Drug: Budesonide 2 mg suppository/Mesalazine 1 g suppository
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per day
Study: NCT00964704
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg iv every 3 weeks
Study: NCT00964704
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
Study: NCT00964704
Drug: trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
Study: NCT00824668
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00824668
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00824668
Drug: insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01919619
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01345669
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily
Study: NCT02982941
Drug: Enoblituzumab
Normalized name: Enoblituzumab
DrugBank: Enoblituzumab (DB15017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoblituzumab administered IV weekly for up to 96 weeks
Study: NCT04186871
Drug: branebrutinib
Normalized name: Branebrutinib
DrugBank: Branebrutinib (DB15347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04186871
Drug: abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04186871
Drug: branebrutinib placebo
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01882504
Drug: gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03145948
Drug: ABBV-553
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered orally.
Study: NCT04478448
Drug: Avigan
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1 tablet contains 200 mg Favipiravir
Study: NCT00015808
Drug: Idebenone
Normalized name: Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04377867
Drug: Abatacept Injection [Orencia]
Normalized name: abatacept Injection [Orencia]
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients on abatacept to control disease symptoms
Study: NCT03029390
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal).
Study: NCT00093522
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00532623
Drug: Gemcitabine plus Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
Study: NCT03928366
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sedation
Study: NCT01042795
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg daily X 16 weeks
Study: NCT00206713
Drug: Sargramostim (Leukine)
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg/kg sargramostim administered SC once daily for 8 weeks
Study: NCT04465292
Drug: Tildrakizumab Prefilled Syringe
Normalized name: tildrakizumab Prefilled Syringe
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
Study: NCT01760772
Drug: Exendin-9
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
Study: NCT00198367
Drug: Cisplatin-Gemzar
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01082471
Drug: Morphine 6-glucuronide
Normalized name: Morphine 6-glucuronide
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01082471
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03595397
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
Study: NCT03595397
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
Study: NCT02549118
Drug: Tenoxicam
Normalized name: tenoxicam
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02549118
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01408472
Drug: NT-501 CNTF Implant
Normalized name: NT 501
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study: NCT03699423
Drug: 0.01% atropine eye drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% atropine sulphate
Study: NCT03699423
Drug: 0.02% atropine eye drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.02% atropine sulphate
Study: NCT03699423
Drug: 0.03% atropine eye drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.03% atropine sulphate
Study: NCT00198367
Drug: Cisplatin-Navelbine-Radiotherapy
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00198367
Drug: Carboplatin-Taxol-Radiotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01760772
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of GLP-1 at 0.3 pmol/kg/min
Study: NCT04375514
Drug: ARO-ENaC
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single or multiple doses of ARO-ENaC by inhalation of nebulized solution
Study: NCT01477489
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
Study: NCT02518373
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
Study: NCT00715208
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005120
Drug: Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00412113
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg
Study: NCT00412113
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 10 mg
Study: NCT00715208
Drug: VELCADE
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00715208
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00052338
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00052338
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00052338
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00038662
Drug: Atrasentan
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01262586
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01262586
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02335281
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g Po perday
Study: NCT00526175
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
Study: NCT00526175
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,5 mg/m2 i.v., days 8, 15, 22 and 28
Study: NCT00526175
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/m2, i.v., days 8 and 15
Study: NCT00526175
Drug: L-Asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
Study: NCT00526175
Drug: Cytosine Arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edad \<1 year 1-2 years 2-3 years \> 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
Study: NCT01755728
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
Study: NCT01418742
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: mCRC patients receiving panitumumab as EGFR inhibitor.
Study: NCT00795301
Drug: Capecitabine, Cetuximab, Oxaliplatin
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01665391
Drug: fresolimumab
Normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg total body weight administered intravenous (IV)
Study: NCT01665391
Drug: fresolimumab
Normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg total body weight administered intravenous (IV)
Study: NCT00526175
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 i.v., days 14-15 and 42-43
Study: NCT00442793
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: As prescribed, 3 times weekly
Study: NCT00442793
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 micrograms/kg iv every 2 weeks
Study: NCT03361735
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular or subcutaneous injection
Study: NCT03361735
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT03361735
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection
Study: NCT01811186
Drug: Oxycodone/naloxone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/naloxone titration
Study: NCT01092052
Drug: NMS-1116354
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily administration for 14 consecutive days followed by 7 days of rest
Study: NCT02804776
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg oral daily for 4 weeks
Study: NCT03998254
Drug: Gardasil
Normalized name: Gardasil
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
Study: NCT00446173
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
Study: NCT00244361
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02028910
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child
Study: NCT03427229
Drug: Vancomycin (before randomization)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
Study: NCT00446173
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mcg/kg Subcutaneously Once Daily
Study: NCT00446173
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg/kg Subcutaneously Once Daily
Study: NCT01786174
Drug: Gilenya
Normalized name: Gilenya
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5mg Gilenya orally by mouth once daily for approximately 28 days
Study: NCT03939520
Drug: pirfenidone and nintedanib
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
Study: NCT03939520
Drug: pirfenidone or nintedanib
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Study: NCT03939520
Drug: pirfenidone or nintedanib
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Study: NCT03134456
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.